Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study

Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study

BackgroundFor a majority of patients with metastatic colorectal cancer (mCRC) with MS stable (MSS) or mismatch repair proficient (pMMR), the role of immunotherapy is undetermined. This study investigated the efficacy and safety of camrelizumab when added to XELOX chemotherapy plus bevacizumab or reg...

Full description

Saved in:
Bibliographic Details
Main Authors: Hong Zhou, Yuehui Wang, Yanfang Lin, Wenjie Cai, Xiaofeng Li, Xiaomeng He
Format: article
Language:EN
Published: Frontiers Media S.A. 2021
Subjects:
colorectal cancer
camrelizumab
immune checkpoint inhibitor
microsatellite stable
bevacizumab
regorafenib
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Online Access:https://doaj.org/article/1778ffc6421b4cb1aa24fb47cd56073e
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/1778ffc6421b4cb1aa24fb47cd56073e

Similar Items